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Abstract: The aim of the present study was to examine the prevalence of metabolic syndrome 
(MS) and its components among obstructive sleep apnea (OSA) patients vs controls, as well 
as to investigate which of these components are strongly associated with the presence of 
OSA in subjects reporting symptoms indicating sleep-disordered breathing. Included were 
83 consecutive male subjects, without known concomitant diseases, who visited an outpatient 
clinic of obesity, diabetes and metabolism. Based on polysomnography, these were divided into 
two groups: OSA patients (n = 53) and controls (n = 30). Parameters indicating MS, according 
to the NCEP ATP III criteria (blood pressure, waist circumference, glucose, triglycerides, and 
HDL-cholesterol levels) were evaluated in both groups. The criteria for MS were fulfilled in 
49 participants. Presence of MS was significantly correlated with the presence of OSA. However, 
after adjustment for BMI, only serum glucose was significantly associated with the presence of 
OSA (P = 0.002). Conversely, the presence of MS was associated with a significant reduction in 
percentage of slow-wave sleep (P = 0.030). In conclusion, these results provide further evidence 
for the association between OSA and MS. Between subjects with MS, elevated serum glucose 
levels indicate a higher probability for the presence of OSA.
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Introduction
Obstructive sleep apnea (OSA) is a common disorder characterized by repetitive 
episodes of partial or complete obstruction of the upper airway during sleep, 
ultimately leading to increased respiratory effort, oxyhemoglobin desaturation, sleep 
fragmentation, and excessive daytime sleepiness.1,2 Several studies have investigated 
the association of OSA with cardiovascular morbidity and mortality, systemic inflam-
mation and impaired glucose metabolism.2–12
Metabolic syndrome (MS) is a combination of factors, including obesity with central 
adiposity, glucose intolerance, dyslipidemia, and hypertension, predisposing patients to the 
development of cardiovascular disease and diabetes.13–15 Its prevalence tends to increase 
worldwide due to the increase of obesity.13,16 The criteria for the diagnosis of metabolic 
syndrome vary according to the definition but, in all definitions, the key components are 
obesity, impaired glucose metabolism, dyslipidemia and hypertension.14,17
The correlation between OSA and MS is complex and incompletely understood.18,19 
Indeed, the independent association between OSA, insulin resistance, and the 
development of type 2 diabetes has been established in numerous works.3,5,6,9,20–22 Thus, 
OSA has been proposed as an extra component of MS, with intermittent hypoxia being 
identified as a potential triggering factor.3,20 However, the evidence for the contribution Vascular Health and Risk Management 2010:6 282
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of OSA to the development of MS is far from conclusive. 
Previous studies in European and East-Asiatic populations 
have demonstrated an independent association between OSA 
and the MS.20,23–25 These studies have used either the National 
Cholesterol Educational Program – Adult Treatment Program 
(NCEP-ATP) III criteria or the definition of the International 
Diabetes Federation (IDF).14,17
Therefore, the aim of the present study was to examine 
the prevalence of MS and its components among OSA 
patients vs. controls, as well as to investigate which of these 
components are strongly associated with the presence of OSA 
in subjects reporting symptoms indicative of sleep-disordered 
breathing.
Materials and methods
Study group
The present study included 83 male subjects, without 
previous diagnosis or treatment for OSA, who were referred 
to the Sleep Laboratory of the Department of Pneumonology 
of the Democritus University of Thrace, Greece, between 
January and June 2006, reporting symptoms indicating 
sleep-disordered breathing (eg, excessive daytime sleepiness, 
snoring, and/or morning headaches, fatigue). These were 
consecutively recruited from the Outpatient Clinic of 
Obesity, Diabetes and Metabolism in the Second Department 
of Internal Medicine of the same institution. Exclusion 
criteria were as follows: previously-diagnosed diabetes 
mellitus (DM); arterial hypertension; any cardiovascular or 
cerebrovascular disease; liver, endocrine, inflammatory, or 
other chronic disease; systemic medication use; smoking. 
The study was conducted in accordance with the Helsinki 
Declaration of Human Rights and all subjects gave their 
informed consent.
Study design
Initial assessment
At first visit, medical history was recorded and physical 
examination was performed. Anthropometrical data 
(age, sex, neck, waist and hip circumferences) along with 
daytime habits (such as smoking, alcohol use, exercise) were 
recorded. Weight and height were measured to the nearest 
kilogram and centimeter respectively, and body mass index 
(BMI) was calculated (BMI = weight/height2). During 
examination, participants were lightly clothed, without 
shoes. Neck circumference was measured at the cricothyroid 
level, waist circumference in the middle between the 12th rib 
and the iliac crest, and hip circumference at the level of 
great trochander, by measuring tape. Diabetes was defined 
by fasting hyperglycemia above 126 mg/dL.26 Diagnosis of 
arterial hypertension was based either on antihypertensive 
treatment with medical history of documented high 
blood pressure, or on measurement of systolic pressure 
140 mmHg and/or measurement of diastolic pressure 
90 mmHg on three separate occasions.27 Diagnosis of MS 
was based on the NCEP-ATP III criteria.17 Sleepiness was 
evaluated by the Greek version of the Epworth Sleepiness 
Scale (ESS).28
Polysomnography (PSG)
All subjects underwent an attended overnight polysom-
nography (Alice® 4, Philips Respironics, Murrysville, PA, 
USA) using a standard montage of electroencephalogram 
(EEG), electroocculogram, electromyogram (EMG), and 
electrocardiogram (ECG) signals, together with pulse 
oxymetry and airflow, detected using combined oronasal 
thermistors. Thoracic cage and abdominal motion were 
recorded by inductive plethysmography. EEG recordings were 
manually scored according to standard criteria. Apnea was 
defined as complete cessation of airflow for 10 sec; hypopnea 
as a 50% reduction in airflow for 10 sec, accompanied by 
4% desaturation or by an EEG-recorded arousal. Apnea 
Hyponea Index (AHI) was defined as the number of apneas 
and hypopneas per hour of polysomnographically-recorded 
sleep time, while Oxygen Desaturation Index (ODI) was 
defined as the number of oxyhemoglobin desaturations 3% 
per hour of polysomnographically recorded sleep time.OSA 
was defined as AHI  5, plus daytime symptoms. PSG was 
performed from 2200 to 0600 hours. Patients with pure or 
mainly central apneas were excluded from the study.
Biochemical analysis of blood samples
Blood samples were obtained the morning after polysomnog-
raphy, between 0800 and 0900 hours, following an overnight 
fast. Total, high-density lipoprotein (HDL)- and low-density 
lipoprotein (LDL)-cholesterol and triglyceride levels were 
measured by enzymatic colorimetric methods, while glucose 
was measured by enzymatic method (Olympus AU640™, 
Olympus Diagnostica GmbH, Hamburg, Germany).
Statistical analysis
Descriptive statistics are expressed as mean ± standard 
deviation (SD). Chi-squared (χ2) tests were used for exploring 
the relationship between two categorical variables. The 
association between the presence of metabolic syndrome 
and the presence of apnea, adjusted for BMI, was determined 
using logistic regression. The same technique was used for 
determining the relationship between the presence of metabolic Vascular Health and Risk Management 2010:6 283
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syndrome and other explanatory variables, either factors or 
covariates. The results are presented as regression coefficients 
or Wald tests, along with their statistical significance. All 
analyses were performed using SPSS v.13 (Statistical Package 
for Social Sciences, Chicago, IL, USA).
Results
Based on polysomnography, subjects were divided into OSA 
patients (n = 53; mean AHI 57.2 ± 26.8 events/hour) and healthy 
controls (n = 30; mean AHI 3.5 ± 1.9 events/hour). General and 
sleep characteristics of both groups are presented in Table 1.
Among the 83 participants, 49 (59%) filled the criteria 
for MS. Specifically, MS was present in 71.7% of the 
OSA patients (38 out of 53) and in 36.7% of the controls 
(11 out of 30). Despite the strong association between the 
presence of metabolic syndrome and sleep apnea (χ2 = 8.91, 
P = 0.003), logistic regression analysis showed that this 
association became marginally non-significant (B = -1.081, 
P = 0.052) when BMI was taken into account.
Looking separately at each component of the metabolic 
syndrome, the presence of OSA was associated with serum 
glucose levels above the cut-off set by NCEP ATP III 
(χ2 = 12.533, P = 0.000),16 with waist circumference above 
the cut-off for each gender (χ2 = 9.974, P = 0.001), and blood 
pressure exceeding the cut-off point (χ2 = 3.374, P = 0.043). 
On logistic regression analysis, however, only the presence 
of increased serum glucose levels was associated with sleep 
apnea adjusted for BMI (B = 2.530, P = 0.002). Table 2 shows 
the estimated regression coefficients of each parameter of MS 
for sleep apnea, along with their statistical significance.
Conversely, the investigation of the correlations between 
sleep or anthropometric characteristics and presence of 
MS yielded only one significant correlation. There was a 
significant negative correlation (B = -0.079, P = 0.030) 
Table 1 Anthropometric, sleep, and metabolic characteristics of the studied population and comparison between obstructive sleep 
apnea patients and controls
Characteristic Total (n = 83) Controls (n = 30) OSA patients (n = 53) P
Age 45.88 ± 9.01 45.47 ± 4.16 46.11 ± 10.87 0.701
BMI (kg/m2) 32.29 ± 6.91 29.04 ± 4.31 34.13 ± 7.44 0.001
Neck circumference (cm) 42.54 ± 3.22 40.53 ± 2.4 43.16 ± 3.19 0.000
Waist circumference (cm) 113.34 ± 13.05 105.13 ± 6.44 114.47 ± 12.95 0.000
Hip circumference (cm) 117.47 ± 19.56 105.93 ± 7.55 118.55 ± 19.14 0.000
WHR 0.97 ± 0.088 0.99 ± 0.04 0.98 ± 0.08 0.254
Systolic blood pressure (mmHg) 137.26 ± 14.34 128.37 ± 7.36 133.28 ± 8.43 0.009
Diastolic blood pressure (mmHg) 82.53 ± 11.44 80.5 ± 7.22 81.23 ± 8.85 0.703
ESS 9.50 ± 5.95 5.9 ± 4.52 11.42 ± 5.78 0.000
AHI (events/hour) 37.76 ± 33.61 3.46 ± 1.89 57.17 ± 26.77 0.000
avSpO2 (%) 91.41 ± 4.30 93.68 ± 1.9 90.12 ± 4.74 0.000
minSpO2 (%) 77.17 ± 10.82 86.37 ± 3.24 71.96 ± 10.12 0.000
TST with SpO2  90% (%TST) 22.25 ± 27.67 4.93 ± 18.27 58.24 ± 26.59 0.000
ODI (events/hour) 38.94 ± 33.44 4.84 ± 3.21 58.24 ± 26.59 0.000
Sleep efficiency (%TST) 86.77 ± 9.92 84.35 ± 8.87 88.7 ± 10.39 0.083
Stage 1 (%TST) 10.94 ± 6.93 8.63 ± 5.08 12.78 ± 7.70 0.017
Stage 2 (%TST) 49.94 ± 13.66 44.58 ± 12.64 54.23 ± 13.10 0.005
Stage 3 + 4 (%TST) 15.55 ± 11.89 19.93 ± 10.96 12.05 ± 11.57 0.008
REM sleep (%TST) 10.83 ± 5.73 11.87 ± 4.26 10.01 ± 6.62 0.202
Glucose (mg/dL) 97.40 ± 30.74 81.77 ± 9 106.25 ± 34.9 0.000
Total cholesterol (mg/dL) 234.11 ± 46.25 226.13 ± 46.16 238.62 ± 46.12 0.240
Triglycerides (mg/dL) 192.30 ± 138.51 163.23 ± 73.03 208.75 ± 162.84 0.151
HDL-cholesterol (mg/dL) 41.31 ± 8.290 42.53 ± 7.51 40.58 ± 8.54 0.301
LDL-cholesterol (mg/dL) 148.85 ± 42.54 142 ± 39.29 152.7 ± 43.63 0.270
Abbreviations: BMI, body mass index;   WHR, waist to hip ratio; ESS, Epworth Sleepiness Scale;   AHI,   Apnea Hypopnea Index; avSpO2, average oxyhemoglobin saturation 
during sleep time; minSpO2, minimum oxyhemoglobin saturation during sleep time;   TST, total sleep time; ODI, oxygen desaturation index; REM, rapid eye movement; HDL, 
high-density lipoprotein; LDL, low density lipoprotein.Vascular Health and Risk Management 2010:6 284
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between MS and the percentage of slow-wave sleep (SWS) 
(ie, stages 3 and 4), in total sleep time. Correlations between 
anthropometrics, sleep characteristics and MS can be seen 
in Table 3.
Discussion
This work explores the association between MS and OSA in 
otherwise-healthy Caucasian male subjects with symptoms 
indicating sleep-related breathing disorders. Our study shows 
an association between those two entities. The association 
between MS and OSA is not a novel finding. MS has already 
been found significantly higher in OSA patients than the 
general population.20,23–25,29 So far, however, investigation 
has focused on detecting MS in OSA patients and showing 
that MS is more frequent in such patients than in the general 
population. The new aspect that this study is attempting 
to examine is the reverse association. To the best of our 
knowledge, this is the first study on otherwise-healthy males 
who were recruited from an Outpatient Clinic of Obesity, 
Diabetes and Metabolism and referred because of symptoms 
suggesting sleep-disordered breathing. In this specific setting, 
prevalence of MS was, naturally, high (almost 6 out of 
10 patients), and its presence was strongly associated with 
OSA. Of note, this association became marginally non-
significant after adjustment for BMI. Peled et al reported 
that BMI did not affect the relationship between the number 
of MS features and OSA severity.29 Nevertheless, their 
study differed from ours in several ways. First, they did not 
recruit selected subjects, free from comorbidities, who were 
regularly attending an Outpatient Obesity Clinic. Secondly, 
they included both males and females, whereas we confined 
the enquiry to males. Finally, they examined a metabolic 
score rather than the presence or not of MS.29 Overall, obesity 
has already been recognized as a potential confounding factor 
in the association between MS and OSA, that needs further 
clarification.20,23–25,29
Importantly, OSA patients exhibited elevated fasting 
glucose levels in comparison to age-matched controls. More 
importantly, increased serum glucose was significantly 
associated with the presence of OSA. Hyperglycemia was the 
only component of MS that showed an association with OSA 
independent of BMI. The increase in serum glucose among 
patients with OSA concurs with previous findings.5,25,30 
Elevated serum glucose is demonstrable in cases of OSA 
among severely obese subjects,25 hypertensive males30 and 
men from the general population.5 The independence from 
BMI has been reported for hypertensive males.30 Our findings 
add to the notion that hyperglycemia is a pivotal diagnostic 
hallmark in patients with OSA. The novelty of the finding 
lies in showing a role for hyperglycemia in a different setting, 
ie, otherwise-healthy males with MS from a specialized 
metabolic clinic, whose symptoms raised suspicion of 
sleep-disordered breathing.
Table 2 Correlations between obstructive sleep apnea and the 
parameters of metabolic syndrome
Parameters of metabolic 
syndrome 
Estimated  
logistic  
coefficient
Wald test 
 
P 
 
Waist circumference exceeding 
102 cm (males) or 
88 cm (females)
0.708 1.250 0.264
Triglycerides level exceeding 
150 mg/dL
-0.313 0.361 0.548
HDL-cholesterol level below 
40 mg/dL (males) or  
50 mg/dL (females)
0.393 0.594 0.441
Glucose levels exceeding  
110 mg/dL
2.530 9.906 0.002
Blood pressure exceeding  
130 mmHg (systolic) or  
85 mmHg (diastolic)
0.399 
 
0.296 
 
0.586 
 
Table 3 Correlations between the presence of metabolic syndrome 
and anthropometric and sleep characteristics of the studied 
population
Characteristic Estimated  
logistic  
coefficient
Wald test P
Age (years) 0.050 2.222 0.136
BMI (kg/m2) 0.062 1.222 0.269
Neck circumference (cm) 0.248 3.461 0.063
Waist circumference (cm) 0.035 1.376 0.241
Hip circumference (cm) 0.033 1.599 0.206
WHR -2.732 0.350 0.554
ESS 0.034 0.373 0.542
AHI (events/hour) 0.008 0.478 0.489
avSpO2 (%) -0.037 0.270 0.604
minSpO2 (%) -0.038 1.260 0.262
TST with SpO2  
 90% (%TST)
0.011 0.850 0.356
ODI (events/hour) 0.011 0.853 0.356
Sleep efficiency (%TST) -0.085 2.257 0.133
Stage 1 (%TST) 0.017 0.120 0.729
Stage 2 (%TST) 0.047 2.294 0.130
Stage 3 + 4 (%TST) -0.079 4.699 0.030
REM sleep (%TST) -0.123 3.316 0.069
Abbreviations: BMI, body mass index; WHR, waist to hip ratio; ESS, Epworth 
  Sleepiness Scale; AHI, Apnea Hypopnea Index; avSpO2, average oxyhemoglobin 
  saturation during sleep time; minSpO2, minimum oxyhemoglobin saturation during 
sleep time; TST, total sleep time; ODI, oxygen desaturation index; REM, rapid eye 
movement.Vascular Health and Risk Management 2010:6 285
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Additionally, MS was associated with altered distribution 
of sleep stages. Indeed, the percentage of slow-wave sleep 
out of total sleep time was reduced in subjects with MS. 
This could indicate inferior sleep quality, although sleep 
efficiency and the proportion of the other sleep stages 
remained unaffected. There is growing concern that the 
suppression of slow-wave sleep may increase the risk for 
the development of type 2 diabetes.31–33 It appears that poor 
sleep quality perpetuates the activation of the sympathetic 
nervous system and exacerbates pre-existing dysregulation of 
the endocrine system. In this context, our finding reinforces 
the emerging importance of the interaction between sleep 
disorders and impaired glucose homeostasis, and suggests 
that this interaction may hold true as early as the stage of 
MS before the development of type 2 diabetes.
This study used the NCEP ATP III definition of MS17 
and not the IDF criteria.14 While the latter are more recent, 
most work has been performed with the former.20,21 Since 
the IDF has suggested diagnosing MS at lower thresholds 
for fasting glucose (ie, 100 mg/dL) and waist circumference 
(94 cm in men and 80 cm in women) than the NCEP ATP 
III (110 mg/dL, 102 cm in men and 88 cm in women, 
respectively), the frequency of MS in OSA patients might 
be expected to rise. Clearly, the newer IDF criteria offer the 
opportunity to re-examine the association between MS and 
OSA. The diversity of criteria reflects the complexity of MS 
and the ever-growing experience of the subject.34 Clearly, 
re-examination with the newer criteria has the potential to 
enrich our knowledge in this field.
The limitations of the present work may be outlined 
as follows. First, it recruited male subjects only, and so 
its findings cannot be applied to females. However, there 
appears to be a different effect of sleep apnea on metabolic 
profile in women, partly, at least, due to different hormonal 
regulation,35,36 and so we chose to focus on male subjects. 
Secondly, our study population is small, and its findings 
need to be viewed with caution. For instance, it is surprising, 
from a clinical point of view, that blood pressure and waist 
circumference were not associated with the presence of 
OSA. The same holds true for the association of slow-wave 
sleep with MS. Although the suppression of slow wave sleep 
has been identified as a risk factor for future diabetes,31–33 
the precise mechanism underlying the association with MS 
would benefit from further clarification. These issues need to 
be re-examined in a larger patient series. Furthermore, there 
are no follow-up data to show the impact of the components 
of MS for the long-term risk of OSA. Obviously, this was 
beyond the scope of this work, which had a cross-sectional 
design. Finally, we did not quantify insulin resistance 
(eg, by the Homeostatic Model Assessment), but we aimed 
to evaluate the utility of very simple metabolic parameters as 
used in everyday practice for the detection of OSA.
This study may have the following practical implications. 
Among men with MS, free from comorbidities, who report 
symptoms suggestive of sleep-disordered breathing, high 
serum glucose is associated with a significant increase in the 
frequency of OSA, even after adjustment for BMI. Moreover, 
our results point to disordered-sleep architecture, with 
impaired sleep quality in the presence of MS. Arguably, it 
appears useful for the clinician treating men with diagnosed 
MS to bear in mind that they may have some reduction 
of sleep quality and that hyperglycemia increases the 
likelihood of overt OSA. Given that OSA itself aggravates 
insulin resistance3,5,9,20,21 and tends to increase cardiovascular 
morbidity,2,12 early specialist referral for diagnosis and 
management of this condition might be anticipated to 
be beneficial. This argument is enhanced by the recent 
recognition that the risk of OSA needs to be addressed in 
patients with frank type 2 diabetes, a condition of more 
profoundly impaired glucose metabolism.37
In conclusion, among male subjects with MS who have 
symptoms indicative of sleep-disordered breathing, elevated 
serum glucose levels increase the likelihood for the presence 
of OSA. Moreover, there is a significant negative correlation 
between MS and the percentage of slow-wave sleep in total 
sleep time, indicating poorer sleep quality in the presence of 
MS. These results provide further evidence for the association 
between OSA and MS. Further work is now needed to shed 
more light on the pathophysiology of this bidirectional 
association, as well as to ascertain whether glucose and/or other 
components of MS can be meaningfully used for appropriate 
referral and early detection of OSA in such patients.
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